DrugStore

Prescription Drug information for consumers & professionals.

Welcome to the most popular, comprehensive and up-to-date drug information resource online. Fast, easy searching of over 24,000 approved medications.

Recent updates to the DrugsStore website and database
Consumer and prescribing information.
Atripla, Azilect, Chantix, Boostrix, Cesamet, Dacogen, Daytrana, Gardasil, Ionsys,
Lucentis, Macugen, Magnevist, Myozyme, Opana, Oracea, Prezista, Relenza,
Seasonique, Solodyn, Sprycel, Tamiflu, Yaz, Zelapar, Zostavax...

New Approval: Brovana
October 9, 2006 - The FDA has approved Brovana Inhalation Solution 15 mcg as a long-term, twice-daily (morning and evening), maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Brovana is the first long-acting beta2-agonist to be approved...

New Approval: Kiacta
October 16, 2006 - Neurochem (International) Limited announced today that it has submitted a complete response to the FDA's August 2006 approvable letter for Kiacta. The Company is seeking marketing approval of its investigational product candidate Kiacta (eprodisate; formerly Fibrillex) for the treatment of Amyloid A amyloidosis. Today, there is still no...

New Application: Saforis
October 13, 2006 - MGI PHARMA, INC. today announced it has received an approvable letter from the FDA for Saforis Powder in UpTec(TM) for Oral Suspension, an investigational therapy for the treatment and prevention of oral mucositis. The FDA has requested an additional phase 3 trial to evaluate the efficacy of Saforis in the proposed indication...

New Application: Bifeprunox
October 12, 2006 - Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals announced today that a NDA was submitted to the FDA for bifeprunox, an investigational atypical antipsychotic for the treatment of schizophrenia. Schizophrenia is a chronic form of psychosis that affects approximately three million North Americans. It is characterized by...

LifeScan One Touch Blood Glucose Test Strips -- Counterfeit Alert
October 13, 2006 -- LifeScan and FDA notified healthcare professionals and the public of counterfeit blood glucose test strips being sold in the United States for use with various models of the One Touch Brand Blood Glucose Monitors used by people with diabetes to measure their blood glucose. The counterfeit test strips potentially could give incorrect blood glucose values--either too high or too low--which might result in a patient taking either too much or too little insulin and lead to serious injury or death... Coumadin (warfarin sodium) October 6, 2006 -- FDA and Bristol-Myers Squibb notified pharmacists and physicians of revisions to the labeling for Coumadin, to include a new patient Medication Guide as well as a reorganization and highlighting of the current safety information to better inform providers and patients... Isotretinoin - Accutane and generic isotretinoin October 6, 2006 -- FDA and the iPLEDGE program notified healthcare professionals and patients of an update to iPLEDGE, a risk management program to reduce the risk of fetal exposure to isotretinoin, that will eliminate one element of the program, the 23 day lock-out period for males and females of non-child bearing potential. This change does not affect female patients of child-bearing potential... Lamictal (lamotrigine) September 29, 2006 -- The FDA notified healthcare professionals and patients of new preliminary information from the North American Antiepileptic Drug Pregnancy Registry that suggests that babies exposed to Lamictal, indicated to treat seizures and bipolar disorder, during the first three months of pregnancy may have a higher chance of being born with a cleft lip or cleft palate. More research is needed to be sure about the possibility of the increased chance of cleft lip or cleft palate developing in babies of pregnant women who take Lamictal. Women who are pregnant and taking Lamictal or who are thinking about taking this medication are urged to not start or stop taking the medication without first talking to their physician...
Avastin (bevacizumab) September 25, 2006 -- Genentech and FDA notified healthcare professionals about revisions to the WARNINGS and ADVERSE REACTIONS sections of the prescribing information to inform healthcare professionals of 1] cases of a rare brain-capillary leak syndrome [reversible posterior leukoencephalopathy syndrome (RPLS)] and 2] postmarketing reports of nasal septum perforation. RPLS is a neurological disorder associated with hypertension, fluid retention and cytotoxic effects of immunosuppressive drugs on the vascular endothelium. The syndrome can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild to severe hypertension may be present, but is not necessary for diagnosis. The onset of symptoms has been reported to occur from 16 hours to 1 year after initiation of Avastin. Magnetic Resonance Imaging (MRI) is necessary to confirm the diagnosis of RPLS.: Drugs list:
Emla Enbrel Endocet Enfamil Enulose Epinephrine Epipen Epogen Ery-Tab Erythrocin Erythromycin Esgic Estrace Estradiol Estratest Etodolac Evista Evoxac Exelon Famotidine Famvir Feldene Felodipine Femara Femhrt Fenofibrate Fentanyl Ferrous-Gluconate Ferrous-Sulfate Fexofenadine Finasteride Fioricet Flagyl Flexeril Flonase Flovent Floxin Fluconazole Fluocinonide Fluoride Fluorouracil Fluoxetine Flurazepam Flurbiprofen Fluticasone Fluvoxamine Focalin Focalin-XR Folic-Acid Foradil Fortamet Forteo Fosamax Fosinopril Fragmin Frova Furosemide Gabapentin Gabitril Gemfibrozil Genotropin Gentamicin Gentian Geodon Gleevec Glimepiride Glipizide Glucagon Glucophage Glucotrol Glucovance Glyburide Glycopyrrolate Griseofulvin Guaifenesin Guanfacine HMS Halcion Haldol Haloperidol Heparin Humalog Humatrope Humira Humulin Hycodan Hydralazine Hydrea Hydro Hydrochlorothiazide Hydrocodone Hydrocodone-APAP Hydrocodone-acetaminophen Hydrocortisone Hydromorphone Hydroquinone Hydroxyurea Hydroxyzine Hyoscyamine Hytrin: (c) Drugstore, 2006